Quotient Biodiagnostics Holdings Limited, a global transfusion diagnostics group, has completed an $11.2m growth equity financing.
The round was led by Galen Partners, a US-based healthcare venture capital investment firm.
The company intends to use the capital to expand US commercial operations, manufacturing and product development operations in Edinburgh, Scotland, and to accelerate the development of its automated transfusion diagnostics platform.
In conjunction with the funding, David Azad and John Wilkerson from Galen Partners will join Quotient’s Board as Non-Executive Directors, along with Thomas A. Bologna, Chairman and CEO of Response Genetics.
Led by Executive Chairman and Founding Shareholder Paul Cowan, the group provides the US blood banking community with trusted transfusion diagnostics products, which are manufactured by Alba Bioscience, its Scotland-based product development and manufacturing arm.
Quotient Biodiagnostics, Inc. is the Group’s North American sales and marketing business.